Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 175,238 shares, a decrease of 41.0% from the May 14th total of 296,872 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 292,130 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. Ascendiant Capital Markets lifted their target price on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research note on Monday, June 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Allarity Therapeutics currently has a consensus rating of “Hold” and an average target price of $10.25.

Institutional Investors Weigh In On Allarity Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares during the last quarter. Jane Street Group LLC purchased a new stake in Allarity Therapeutics in the 2nd quarter worth about $27,000. XTX Topco Ltd purchased a new stake in Allarity Therapeutics in the 4th quarter worth about $36,000. Citadel Advisors LLC purchased a new stake in Allarity Therapeutics in the 3rd quarter worth about $149,000. Finally, Capital Advisors Inc. OK purchased a new stake in Allarity Therapeutics in the 4th quarter worth about $108,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Price Performance

NASDAQ ALLR opened at $1.48 on Tuesday. The stock has a market capitalization of $23.55 million, a price-to-earnings ratio of -2.06 and a beta of 0.52. Allarity Therapeutics has a one year low of $0.77 and a one year high of $2.35. The business’s fifty day moving average is $1.45 and its 200-day moving average is $1.22.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Research analysts expect that Allarity Therapeutics will post -0.92 EPS for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.